Question
Does a booster dose provide clinical benefit against symptomatic infection and serious illness due to COVID-19 in persons 60 years and older who are fully vaccinated with the Pfizer-BioNTech vaccine?
Conclusion
A booster (third) dose of the BNT162b2 mRNA vaccine from Pfizer-BioNTech provides significant additional protection against both infection and serious illness. (LOE = 2b)
Recent Posts
- Surgery is no better than nonoperative treatment for Achilles tendon rupture in adults
- Another study fails to find PRP injections effective for adults with degenerative joint disease of the knee
- Short-term benefit from ultrasonography-guided steroid injection for Achilles tendinopathy
- How do ibuprofen, ketorolac, and diclofenac compare for the treatment of acute, nonradicular low back pain in adults?
- Is there an association between gastric cancer and the use of proton pump inhibitors?